{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T18:17:54Z","timestamp":1778869074359,"version":"3.51.4"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014943","name":"Sarepta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014943","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018043","name":"Kitzman Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018043","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018268","name":"Children's Miracle Network Hospitals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01GM-119186"],"award-info":[{"award-number":["R01GM-119186"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 AR-081018"],"award-info":[{"award-number":["R21 AR-081018"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Methods & Clinical Development"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.omtm.2023.101147","type":"journal-article","created":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T22:37:02Z","timestamp":1698878222000},"page":"101147","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Development of capsid- and genome-modified optimized AAVrh74 vectors for muscle gene therapy"],"prefix":"10.1016","volume":"31","author":[{"given":"Jakob","family":"Shoti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keyun","family":"Qing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geoffrey D.","family":"Keeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongsheng","family":"Duan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry J.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1168-8034","authenticated-orcid":false,"given":"Arun","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtm.2023.101147_bib1","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-associated virus vector as a platform for gene therapy delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtm.2023.101147_bib2","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering adeno-associated virus vectors for gene therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/j.omtm.2023.101147_bib3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","article-title":"Current Clinical Applications of In\u00a0Vivo Gene Therapy with AAVs","volume":"29","author":"Mendell","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.101147_bib4","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1146\/annurev-virology-092818-015530","article-title":"Recombinant adeno-associated virus gene therapy in light of Luxturna (and Zolgensma and Glybera): Where are we, and how did we get here? (2019)","volume":"6","author":"Keeler","year":"2019","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.omtm.2023.101147_bib5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1089\/hum.2019.29101.trf","article-title":"Gene therapy enters its fourth decade","volume":"31","author":"Flotte","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.101147_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/hum.2015.29017.asr","article-title":"Adeno-associated virus: The naturally occurring virus versus the recombinant vector","volume":"27","author":"Srivastava","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.101147_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/156652311796150354","article-title":"High, K. Immune responses to AAV in clinical trials. (2011)","volume":"11","author":"Mingozzi","year":"2011","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/j.omtm.2023.101147_bib8","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.ymthe.2019.12.010","article-title":"AAV vector immunogenicity in humans: A long journey to successful gene transfer","volume":"28","author":"Verdera","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.101147_bib9","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1089\/hum.2020.217","article-title":"Letter to the Editor","volume":"31","author":"Shieh","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.101147_bib10","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1089\/hum.2018.012","article-title":"Micro-dystrophin gene therapy goes systemic in Duchenne muscular dystrophy patients","volume":"29","author":"Duan","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.101147_bib11","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/mt.2011.237","article-title":"Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector","volume":"20","author":"Bowles","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.101147_bib13","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/hum.2022.29198.bfs","article-title":"After patient death, FDA places hold on Pfizer Duchenne muscular dystrophy gene therapy trial","volume":"33","author":"Philippidis","year":"2022","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.101147_bib14","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after high-dose rAAV9 gene therapy in a patient with Duchenne muscular dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2023.101147_bib15","first-page":"91","article-title":"Sarepta's DMD gene therapy falls flat","volume":"20","author":"Mullard","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.omtm.2023.101147_bib17","doi-asserted-by":"crossref","first-page":"7827","DOI":"10.1073\/pnas.0802866105","article-title":"Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. (2008)","volume":"105","author":"Zhong","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.omtm.2023.101147_bib18","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1038\/mt.2010.172","article-title":"High-efficiency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines","volume":"18","author":"Markusic","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.101147_bib19","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2012-10-460733","article-title":"Engineered AAV vector minimizes in\u00a0vivo targeting of transduced hepatocytes by capsid-specific CD8+ T\u00a0cells","volume":"121","author":"Martino","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2023.101147_bib20","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1128\/JVI.02581-14","article-title":"Enhanced transgene expression from recombinant single-stranded D-sequence-substituted adeno-associated virus vectors in human cell lines in\u00a0vitro and in murine hepatocytes in\u00a0vivo","volume":"89","author":"Ling","year":"2015","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2023.101147_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/hgtb.2016.054","article-title":"Development of optimized AAV serotype vectors for high-efficiency transduction at further reduced doses","volume":"27","author":"Ling","year":"2016","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.omtm.2023.101147_bib22","doi-asserted-by":"crossref","first-page":"e59142","DOI":"10.1371\/journal.pone.0059142","article-title":"Optimization of the capsid of recombinant adeno-associated virus 2 (AAV2) vectors: The final threshold?","volume":"8","author":"Aslanidi","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.omtm.2023.101147_bib23","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1089\/hum.2019.255","article-title":"Dose-escalation study of systemically delivered rAAVrh74.MHCK7.micro-dystrophin in the mdx mouse model of Duchenne muscular dystrophy","volume":"32","author":"Potter","year":"2021","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.101147_bib24","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.virol.2008.08.027","article-title":"Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression","volume":"381","author":"Zhong","year":"2008","journal-title":"Virology"},{"key":"10.1016\/j.omtm.2023.101147_bib25","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/S1525-0016(16)32820-9","article-title":"The role of glucocorticoid receptor signaling in adeno-associated virus 2 infection","volume":"24","author":"Ling","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.101147_bib26","doi-asserted-by":"crossref","first-page":"9835","DOI":"10.1128\/JVI.72.12.9835-9843.1998","article-title":"Adeno-associated virus type 2-mediated gene transfer: role of epidermal growth factor receptor protein tyrosine kinase in transgene expression","volume":"72","author":"Mah","year":"1998","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.omtm.2023.101147_bib27","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1089\/hum.2020.187","article-title":"AAV Vectors: Are they safe?","volume":"31","author":"Srivastava","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.omtm.2023.101147_bib28","doi-asserted-by":"crossref","first-page":"e1002533","DOI":"10.1371\/journal.pbio.1002533","article-title":"Revised estimates for the number of human and bacteria cells in the body","volume":"14","author":"Sender","year":"2016","journal-title":"PLoS Biol."},{"key":"10.1016\/j.omtm.2023.101147_bib29","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","article-title":"Assessment of Systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: A nonrandomized controlled trial","volume":"77","author":"Mendell","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.omtm.2023.101147_bib30","first-page":"e2304","article-title":"Life expectancy in Duchenne muscular dystrophy: Reproduced individual patient data meta-analysis","volume":"97","author":"Broomfield","year":"2021","journal-title":"Neurol."},{"key":"10.1016\/j.omtm.2023.101147_bib31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy (2021)","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.omtm.2023.101147_bib32","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1038\/s41467-020-19230-w","article-title":"Identification of a myotropic AAV by massively parallel in\u00a0vivo evaluation of barcoded capsid variants","volume":"11","author":"Weinmann","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omtm.2023.101147_bib33","doi-asserted-by":"crossref","first-page":"eabn4704","DOI":"10.1126\/sciadv.abn4704","article-title":"Semirational bioengineering of AAV vectors with increased potency and specificity for systemic gene therapy of muscle disorders","volume":"8","author":"El Andari","year":"2022","journal-title":"Sci. Adv."},{"key":"10.1016\/j.omtm.2023.101147_bib34","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"Tabebordbar","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.omtm.2023.101147_bib35","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nm1358","article-title":"Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat. Med."},{"key":"10.1016\/j.omtm.2023.101147_bib36","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. (2011)","volume":"365","author":"Nathwani","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2023.101147_bib37","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1056\/NEJMoa1407309","article-title":"Long-term safety and efficacy of factor IX gene therapy in hemophilia B. (2014)","volume":"371","author":"Nathwani","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.omtm.2023.101147_bib38","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1182\/blood.2019004625","article-title":"BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression","volume":"137","author":"Konkle","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.omtm.2023.101147_bib43","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.omtn.2023.05.014","article-title":"Rationale and strategies for the development of safe and effective optimized AAV vectors for human gene therapy","volume":"32","author":"Srivastava","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2023.101147_bib44","doi-asserted-by":"crossref","first-page":"680","DOI":"10.2144\/99264st03","article-title":"Two-stage PCR protocol allowing introduction of multiple mutations, deletions and insertions using QuikChange Site-Directed Mutagenesis","volume":"26","author":"Wang","year":"1999","journal-title":"Biotechniques"},{"key":"10.1016\/j.omtm.2023.101147_bib45","doi-asserted-by":"crossref","first-page":"3375","DOI":"10.1093\/nar\/25.16.3375","article-title":"Quantitative DNA slot blot analysis: inhibition of DNA binding to membranes by magnesium ions","volume":"25","author":"Kube","year":"1997","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.omtm.2023.101147_bib46","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1089\/hgtb.2012.090","article-title":"Limitations of encapsidation of recombinant self-complementary adeno-associated viral genomes in different serotype capsids and their quantitation","volume":"23","author":"Wang","year":"2012","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.omtm.2023.101147_bib47","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.omtm.2020.05.019","article-title":"Role of essential metal ions in AAV vector-mediated transduction (2020)","volume":"18","author":"Rambhai","year":"2020","journal-title":"Mol. Ther. Meth. Clin. Dev."},{"key":"10.1016\/j.omtm.2023.101147_bib48","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.omtn.2020.03.009","article-title":"Enhanced transduction of human hematopoietic stem cells by AAV6 vectors: Implications in gene therapy and genome editing","volume":"20","author":"Yang","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtm.2023.101147_bib49","doi-asserted-by":"crossref","first-page":"12714","DOI":"10.1074\/jbc.M310548200","article-title":"Heat-shock treatment-mediated increase in transduction by recombinant adeno-associated virus 2 vectors is independent of the cellular heat-shock protein 90","volume":"279","author":"Zhong","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.omtm.2023.101147_bib50","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/sj.mt.6300170","article-title":"A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis","volume":"15","author":"Zhong","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtm.2023.101147_bib51","doi-asserted-by":"crossref","first-page":"1033615","DOI":"10.3389\/fmicb.2022.1033615","article-title":"Development of an AAV DNA-based synthetic vector for the potential gene therapy of hemophilia in children","volume":"13","author":"Shoti","year":"2022","journal-title":"Front. Microbiol."}],"container-title":["Molecular Therapy Methods & Clinical Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123001869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2329050123001869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T17:54:16Z","timestamp":1778867656000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2329050123001869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":45,"alternative-id":["S2329050123001869"],"URL":"https:\/\/doi.org\/10.1016\/j.omtm.2023.101147","relation":{},"ISSN":["2329-0501"],"issn-type":[{"value":"2329-0501","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of capsid- and genome-modified optimized AAVrh74 vectors for muscle gene therapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Methods & Clinical Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtm.2023.101147","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"101147"}}